Pfizer(US:PFE) The Motley Fool·2026-02-04 04:15Market Overview - Concerns exist regarding a potential market crash in 2026, with historical data suggesting a bear market may be imminent due to high valuations, particularly in the AI sector [1][5]. Company Analysis: Pfizer - Pfizer's market cap stands at $152 billion, with shares currently priced at $25.77, reflecting a decline of 3.34% [8]. - The company is facing challenges as it will lose patent exclusivity for key products like Eliquis and Xtandi in the coming years, which may impact its financial performance [7]. - Despite recent struggles, Pfizer has a robust pipeline in therapeutic areas such as oncology and weight management, and is leveraging AI to enhance operational efficiency [9]. - The company's earnings remain resilient, and it is trading at 9 times forward earnings, significantly lower than the healthcare sector average of 18.6, indicating potential undervaluation [9]. - In the event of an AI-driven market crash, Pfizer's stock is expected to decline less than major AI companies, positioning it favorably for long-term recovery [10].